These findings indicate that copper chelation can affect the oncogene-driven signaling pathway in melanoma and that restricting copper levels in BRAFi/MEKi-resistant cells can be beneficial for melanoma patients because of the frequent reactivation of the BRAF/MEK/ERK signaling pathway, thereby creating a potential therapeutic window for copper chelators (Fig. 4) [156]. Here, MAPK1 is linked to melanoma.